174 related articles for article (PubMed ID: 38863235)
1. Native State Stabilization of Amyloidogenic Proteins by Kinetic Stabilizers: Inhibition of Protein Aggregation and Clinical Relevance.
Xx P; Raymandal B; Mondal S
ChemMedChem; 2024 Jun; ():e202400244. PubMed ID: 38863235
[TBL] [Abstract][Full Text] [Related]
2. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
Yoshida K; Higuchi K; Ikeda S
Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
[TBL] [Abstract][Full Text] [Related]
3. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
Julius RL; Hawthorne MF
Drug News Perspect; 2008 Jun; 21(5):258-66. PubMed ID: 18596990
[TBL] [Abstract][Full Text] [Related]
4. The systemic amyloidoses.
Buxbaum JN
Curr Opin Rheumatol; 2004 Jan; 16(1):67-75. PubMed ID: 14673392
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System.
Buxbaum JN; Johansson J
Front Neurosci; 2017; 11():119. PubMed ID: 28360830
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
7. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
9. Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses.
Ikeda T; Hori Y; Sohma Y; Kanai M; Tomita T
Adv Exp Med Biol; 2021; 1339():415-422. PubMed ID: 35023134
[TBL] [Abstract][Full Text] [Related]
10. Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis.
Lewkowicz E; Gursky O
Biophys Chem; 2022 Jan; 280():106699. PubMed ID: 34773861
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of systemic amyloid diseases.
Obici L; Perfetti V; Palladini G; Moratti R; Merlini G
Biochim Biophys Acta; 2005 Nov; 1753(1):11-22. PubMed ID: 16198646
[TBL] [Abstract][Full Text] [Related]
12. Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.
Morgan GJ; Buxbaum JN; Kelly JW
Hemato; 2021 Dec; 2(4):645-659. PubMed ID: 35757512
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the Mechanisms Driving Transthyretin Amyloidosis.
Bezerra F; Saraiva MJ; Almeida MR
Front Mol Neurosci; 2020; 13():592644. PubMed ID: 33362465
[TBL] [Abstract][Full Text] [Related]
14. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
16. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
[TBL] [Abstract][Full Text] [Related]
17. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis.
Ferreira N; Saraiva MJ; Almeida MR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875761
[TBL] [Abstract][Full Text] [Related]
18. [Amyloidosis: a model of misfolded protein disorder].
Grateau G; Verine J; Delpech M; Ries M
Med Sci (Paris); 2005; 21(6-7):627-33. PubMed ID: 15985206
[TBL] [Abstract][Full Text] [Related]
19. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
20. Systemic amyloidosis: novel therapies and role of biomarkers.
Nuvolone M; Merlini G
Nephrol Dial Transplant; 2017 May; 32(5):770-780. PubMed ID: 27540044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
